CN104220076A - 用于治疗呈现至少一种炎性组分的肠道疾病的方法 - Google Patents

用于治疗呈现至少一种炎性组分的肠道疾病的方法 Download PDF

Info

Publication number
CN104220076A
CN104220076A CN201380017800.8A CN201380017800A CN104220076A CN 104220076 A CN104220076 A CN 104220076A CN 201380017800 A CN201380017800 A CN 201380017800A CN 104220076 A CN104220076 A CN 104220076A
Authority
CN
China
Prior art keywords
budesonide
composition
compositions
patient
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380017800.8A
Other languages
English (en)
Chinese (zh)
Inventor
卢吉·摩洛
杰拉尔德·托马斯·普洛尔
温德尔·维伦加
迈克尔·芳菁·黄
爱默生·大卫·巴拉德二世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Santarus Inc
Original Assignee
Cosmo Technologies Ltd
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd, Santarus Inc filed Critical Cosmo Technologies Ltd
Priority to CN201910974077.1A priority Critical patent/CN110693890A/zh
Publication of CN104220076A publication Critical patent/CN104220076A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380017800.8A 2012-02-13 2013-02-13 用于治疗呈现至少一种炎性组分的肠道疾病的方法 Pending CN104220076A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910974077.1A CN110693890A (zh) 2012-02-13 2013-02-13 用于治疗呈现至少一种炎性组分的肠道疾病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261598308P 2012-02-13 2012-02-13
US61/598,308 2012-02-13
PCT/EP2013/052838 WO2013120881A1 (en) 2012-02-13 2013-02-13 Method for treating intestinal diseases presenting at least one inflammatory component

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910974077.1A Division CN110693890A (zh) 2012-02-13 2013-02-13 用于治疗呈现至少一种炎性组分的肠道疾病的方法

Publications (1)

Publication Number Publication Date
CN104220076A true CN104220076A (zh) 2014-12-17

Family

ID=47722264

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380017800.8A Pending CN104220076A (zh) 2012-02-13 2013-02-13 用于治疗呈现至少一种炎性组分的肠道疾病的方法
CN201910974077.1A Pending CN110693890A (zh) 2012-02-13 2013-02-13 用于治疗呈现至少一种炎性组分的肠道疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910974077.1A Pending CN110693890A (zh) 2012-02-13 2013-02-13 用于治疗呈现至少一种炎性组分的肠道疾病的方法

Country Status (15)

Country Link
US (5) US20150017239A1 (enExample)
EP (1) EP2814495B1 (enExample)
JP (2) JP2015506999A (enExample)
CN (2) CN104220076A (enExample)
AU (1) AU2013220464A1 (enExample)
BR (1) BR112014020095A8 (enExample)
CA (1) CA2864065A1 (enExample)
DK (1) DK2814495T3 (enExample)
ES (1) ES2882880T3 (enExample)
HK (1) HK1204927A1 (enExample)
IL (1) IL234054A0 (enExample)
IN (1) IN2014DN06662A (enExample)
PT (1) PT2814495T (enExample)
RU (1) RU2649807C2 (enExample)
WO (1) WO2013120881A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585164A (zh) * 2019-10-08 2019-12-20 苏州弘森药业股份有限公司 一种艾司奥美拉唑镁碳酸氢钠胶囊的制作方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2974864B1 (fr) * 2011-05-04 2016-05-27 Snecma Rotor de turbomachine avec moyen de retenue axiale des aubes
US10375513B2 (en) * 2013-05-01 2019-08-06 3 Electric Sheep Pty Ltd Event notification systems and methods
WO2015071812A1 (en) * 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
US10327034B2 (en) * 2014-03-27 2019-06-18 Tvu Networks Corporation Methods, apparatus and systems for exchange of video content
WO2019092614A1 (en) 2017-11-10 2019-05-16 Cosmo Technologies Ltd. Oral rifamycin sv compositions
EP3501496A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Liquid delivery composition
CN119185229A (zh) * 2023-06-26 2024-12-27 湖南慧泽生物医药科技有限公司 一种含皮质类固醇的药物组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
US20120021052A1 (en) * 1999-06-14 2012-01-26 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19849737A1 (de) * 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US8476233B2 (en) * 2003-08-29 2013-07-02 Therapeutic Research, Llc Methods for treatment for ulcerative colitis in mammals
US20100305076A1 (en) * 2006-09-13 2010-12-02 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
US20120021052A1 (en) * 1999-06-14 2012-01-26 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TURSI A, ET AL.: "Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon", 《DIGESTIVE AND LIVER DISEASE》 *
白文元 等: "布地奈德治疗炎性肠病的机制与疗效", 《临床药物治疗杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585164A (zh) * 2019-10-08 2019-12-20 苏州弘森药业股份有限公司 一种艾司奥美拉唑镁碳酸氢钠胶囊的制作方法

Also Published As

Publication number Publication date
IL234054A0 (en) 2014-09-30
CN110693890A (zh) 2020-01-17
IN2014DN06662A (enExample) 2015-05-22
RU2014137128A (ru) 2016-04-10
ES2882880T3 (es) 2021-12-03
US20200163888A1 (en) 2020-05-28
WO2013120881A1 (en) 2013-08-22
JP2017210476A (ja) 2017-11-30
BR112014020095A2 (enExample) 2017-06-20
US20130209559A1 (en) 2013-08-15
PT2814495T (pt) 2021-08-19
BR112014020095A8 (pt) 2017-07-11
JP6472063B2 (ja) 2019-02-20
RU2649807C2 (ru) 2018-04-04
EP2814495A1 (en) 2014-12-24
US20150017239A1 (en) 2015-01-15
US20140187517A1 (en) 2014-07-03
AU2013220464A1 (en) 2014-09-04
EP2814495B1 (en) 2021-07-07
US20130225537A1 (en) 2013-08-29
JP2015506999A (ja) 2015-03-05
DK2814495T3 (da) 2021-08-23
CA2864065A1 (en) 2013-08-22
HK1204927A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
JP6472063B2 (ja) 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
CN110996915B (zh) 考来烯胺丸粒、口服考来烯胺制剂及其用途
JP7422827B2 (ja) コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN108601744B (zh) 口服考来烯胺制剂及其用途
RU2750937C2 (ru) Пероральный состав холестирамина и его применение
EP1172100B1 (en) Oral solid pharmaceutical formulations with ph-dependent multiphasic release
US10555907B2 (en) Controlled-release solid dosage forms of mesalamine
CN105658207A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
CN105073127A (zh) 用于治疗肠纤维化的口服类固醇制剂
JP3633936B2 (ja) センナ剤形
TWI516285B (zh) 含聚葡萄糖胺的劑型
CN108175849B (zh) 聚普瑞锌口服制剂及在制备溃疡性结肠炎药物中的应用
RU2401106C1 (ru) Твердая лекарственная форма, обладающая слабительной активностью, и способ ее получения (варианты)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141217